The South Korean market for targeted therapy prescribed to treat human epidermal growth factor receptor 2 (HER2)-positive breast cancer has exceeded 200 billion won in sales last year. Two domestically developed biosimilars increased the market influence and made up for the sale revenue void in the original by the original maker’s follow-on drugs, such as Kadcyla and Perjeta, breaking the market sales record.

On Mar. 11, a pharmaceutical market research firm IQVIA reported the trastuzumab drug market size last year dropped to 99 billion won by year-on-year 4.8 percent. The market size increased for two consecutive years since it plummeted from 103.4 billion won in 2016 to 83.6 billion won in 2017, and rec